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Clopidogrel Alone is Not Sufﬁcient to Prevent Stent Thrombosis in Diabetic
Patients Requiring Warfarin.
Pongpeera Taytawat1, Dana Villines1, Catherine Kallal1, Lloyd W. Klein2
1Illinois Masonic Medical Center, Chicago, IL, 2Rush Medical College, Chicago, IL
Background: Triple therapy with ASA, clopidogrel and warfarin (ACW) is associated
with increased bleeding, but there is no data that evaluates whether clopidogrel and
warfarin without ASA (CW) is sufﬁcient in preventing stent thrombosis (ST). This
study tested whether omitting ASA in patients on warfarin and clopidogrel who
received either BMS or DES was effective and decreased bleeding.
Methods: 396 consecutive patients undergoing PCI at a single urban center were
enrolled. All were discharged on clopidogrel 75 mg. Patients already on warfarin were
continued. The choice to start ASA 325 mg was at the discretion of the cardiologist.
Patients were followed for at least 1 year. The drug regimen selected was maintained
for at least 1 month after BMS and 1 year after DES. Primary endpoints were all-cause
mortality, MI, stroke, ST, target vessel revascularization. Secondary endpoints
included bleeding events.
Results: Baseline characteristics are shown. The indication for warfarin was atrial
ﬁbrillation in 74% and mechanical valve 12%; the remainder included venous
thromboembolism, severe systolic dysfunction, and the presence of LV thrombus.
Multivariate analyses showed diabetes to be a statistically signiﬁcant determinant
of ST.P
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warfarin. ACW reduces the incidence of ST and lowers all-cause mortality but is
associated with increased bleeding risk. Importantly, CW prevents ST in non-diabetic
patients who require warfarin with less bleeding events, and may be the preferred
antithrombotic therapy in this subgroup.
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Platelet Reactivity Variation Following Ticagrelor Maintenance Dose Allows
Noncompliance Diagnosis By Platelet Function Testing.
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Background: Interindividual variability in platelet response to thienopyridines has
been implicated as a reason making platelet function testing (PFT) unsuitable for
diagnosing drug noncompliance. Because of variability in platelet response to tica-
grelor might be more limited, we aimed to assess PFT usefulness to detect noncom-
pliance to ticagrelor.
Methods: Over 15 months period all patients who were discharged on ticagrelor 90
mg bid maintenance dose were invited for clinical follow-up and PFT at 1 month post
discharge. We studied platelet reactivity (PR) in 211 patients who were self-reported
as compliant to therapy using the VerifyNow P2Y12 function assay (in PRU).
Results: There were 175(82.9 %) men, with a median (Q1-Q3) age of 59.0(51.0-69.0)
years. PR frequency distribution is depicted in Figure. Apart from 3 patients, PR
varied within a narrow range with quartile coefﬁcient of dispersion ¼ 0.65. The 3
patients were invited for ticagrelor administration under medical surveillance and re-
PFT. Case 1 and 2 (in red) admitted not taking regularly ticagrelor at 1 month visit and
at re-PTF had 5 PRU and 88 PRU, respectively, supporting the diagnosis of drug
noncompliance. Case 3 was receiving phenytoin, whose co-administration may lead to
a decrease in exposure and efﬁcacy of ticagrelor and exhibited 149 PRU at re-PTF.
Conclusions: In patients under chronic ticagrelor treatment and in the absence of co-
medication possibly leading to a decrease in its efﬁcacy, an increased PR should
strongly raise the suspicion of noncompliance. PFT may be a useful tool for
noncompliance to ticagrelor detection.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-160
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Background: P2Y12 inhibitor switching has appeared in clinical practice as
a consequence of prasugrel and ticagrelor availability, apart from clopidogrel, for use
in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary
intervention (PCI). In-hospital P2Y12 inhibitor switching has not been adequately
studied.
Methods: In the context of the GReek AntiPlatelet REgistry (GRAPE) we assessed
the prevalence, predictive factors and short-term outcome of in-hospital P2Y12
inhibior switching inACS patients undergoing PCI.
Results: We recruited 1434 patients. Switching occurred in 526(36.7%) patients of
which in the form of clopidogrel to a novel agent, novel agent to clopidogrel and
between prasugrel and ticagrelor in 480(91.2%), 26(5.0%) and 20(3.8%) patients,
respectively. Age75 years, presentation to non PCI-capable hospital, history of
stroke/transient ischemic attack, asthma/chronic obstructive pulmonary disease and
regional trends emerged as predictive factors of switching to a novel agent. At
combined in-hospital and one-month follow-up upgrading to a novel agent did not
confer any ischemic or bleeding difference than novel agent constant administration,
while it was accompanied by higher Bleeding Academic Research Consortium
(BARC) type 1 (21.9%) and BARC any type (28.3%) bleeding events compared to
only clopidogrel administration (8.7% and 11.9%, respectively), p<0.001 for both in
propensity matched pairs analysis.
Conclusions: In a real-life experience with contemporary antiplatelet treatment in
ACS patients undergoing PCI, in-hospital switching represents common clinical
practice. Clinical factors and regional practice differences seem to affect this strategy's
choice, while P2Y12 inhibitor upgrade may be associated with higher than clopidogrel
risk of bleeding.
TCT-161
The administration of a loading dose has no additive effect on platelet
aggregation during the switch from ongoing clopidogrel treatment to ticagrelor
in patients with Acute Coronary Syndrome
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Background: Ticagrelor (TICA) was more efﬁcient than clopidogrel (CLO) in pre-
venting cardiovascular events after Acute Coronary Syndrome (ACS) in the PLATO
trial. However, it was associated with a higher incidence of non-procedural bleedings.
A TICA loading dose could be unnecessary in patients with ongoing CLO therapy.
Aim of the present study was to verify whether the administration of a loading dose
leads to an additional inhibition of platelet aggregation during the switch from
ongoing CLO to TICA therapy.
Methods: Fifty patients with ACS and on CLO treatment were randomly assigned to
a starting dose of TICA of 90mg or 180mg, on top of aspirin treatment. Platelet (PLT)
aggregation was measured using Multiple Electrode Aggregometry (MEA) at 0, 2, 6,acts/POSTER/Antiplatelets and Antithrombins B51
Table. Base-Case Estimates of 5-Year Treatment Costs and Quality-Adjusted
Life-Years
Treatment
Strategy Germany Italy France Spain
The
Netherlands
Universal
Ticagrelor
Costs (V) 19,611 19,806 19,287 19,355 19,058
QALYs 3.919 3.858 3.764 3.822 3.910
PRA-Driven
Ticagrelor
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Aggregometry (LTA).
Results: No relevant difference in platelet aggregation between the two study arms
was observed at baseline (p¼0.256). Residual platelet aggregation measured using
MEA was signiﬁcantly reduced in both arms 2h after the ﬁrst administration of TICA
(both p<0.001). Most interestingly, no difference in aggregation was found 2 hours
after the switch to TICA (17672 vs 18160 AUmin, p¼0.281). Similar ﬁndings
were conﬁrmed with LTA.
Conclusions: Switching from ongoing CLO therapy to TICA without a loading dose
is safe and is not associated to a lower degree of PLT inhibition in patients with ACS.
Larger trials are needed to conﬁrm the present results on a clinical endpoint, as
incidence of bleedings.Costs (V) 19,195 19,168 18,965 18,851 18,633
QALYs 3.910 3.849 3.756 3.814 3.902
ICER vs. PRA-
Driven
Ticagrelor
46,222 70,889 40,250 63,000 53,125
Universal
Prasugrel
Costs (V) 19,636 19,373 19,059 19,034 18,934
QALYs 3.875 3.815 3.722 3.780 3.867
PRA-Driven
Prasugrel
Costs (V) 19,205 18,984 18,867 18,715 18,581
QALYs 3.891 3.831 3.738 3.796 3.883
ICER vs. PRA-
Driven
Prasugrel
Dominated Dominated Dominated Dominated Dominated
ICER¼incremental cost-effectiveness ratio; QALY¼quality-adjusted life-year; PRA¼platelet
reactivity assay; V¼EurosTCT-162
Universal Versus Platelet Reactivity Assay-Driven Use of P2Y12 Inhibitors in
Acute Coronary Syndrome Patients: Cost-Effectiveness Analyses from Five
European Perspectives
Craig I. Coleman1, Brendan L. Limone1
1University of Connecticut, Hartford, CT
Background: Platelet reactivity assays (PRAs) can predict patients' likely response to
clopidogrel. We assessed the cost-effectiveness of universal compared to PRA-driven
selection of ticagrelor or prasugrel for acute coronary syndrome (ACS) patients living
in multiple European countries.
Methods: An Markov model was used to calculate 5-year costs (2013V), quality-
adjusted life-years and incremental cost-effectiveness ratios (ICERs) for 1-year of
universal ticagrelor or prasugrel (given to all) compared to each agents' corresponding
PRA-driven strategy (ticagrelor/prasugrel in those with high platelet reactivity [HPR,
>208 on the VerifyNow P2Y12 assay, Accumetrics, San Diego, CA], others given
generic clopidogrel]. We assumed patients had their index ACS event at 65-70 years
of age and had a 42.7% incidence of HPR post-revascularization. The analysis was
conducted from the perspective of 5 different European countries (Germany, Italy,
France, Spain and The Netherlands) and used a 1-year cycle length. Efﬁcacy and
safety data for P2Y12 Inhibitors were taken from multinational randomized trials and
adjusted using country-speciﬁc epidemiologic data.
Results: Neither universal ticagrelor nor prasugrel were found to be cost-effective (all
ICERs >40,250V/QALY) compared to their corresponding PRA-driven strategies in
any of the countries evaluated (Table). Results were sensitive to differences in P2Y12
Inhibitors costs and drug-speciﬁc relative risks of major adverse cardiac events. Monte
Carlo simulation suggested universal ticagrelor or prasugrel were cost-effective in
only 29-44% and 11-17% of 10,000 iterations compared to their respective PRA-
driven strategies, when applying a willingness-to-pay threshold¼V30,000/QALY.B52 JACC Vol 62/18/Suppl B j October 27–NovemConclusions: The universal use of newer P2Y12 inhibitors is not likely cost-effective
compared to PRA-driven strategies.
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Background: Paroxysmal atrial ﬁbrillation (AF) is frequent in patients undergoing
percutaneous coronary intervention (PCI), but optimum antithrombotic therapy has
not been deﬁned, and whether patients with paroxysmal AF in sinus rhythm (SR) at
the time of PCI require anticoagulation concurrent with DAPT is unknown.
Methods:We evaluated 291 consecutive patients from 2 university Hospitals (US and
Europe), with paroxysmal non-valvular AF who were in SR at the time of PCI
between 2009 and 2011 prescribed triple (TT, n¼98; 34%) or dual antithrombotic
therapy (DAPT, n¼193; 66%) post PCI and compared rates of major adverse
cardiovascular events (MACCE ¼ death, myocardial infarction [MI], revasculariza-
tion, stroke, peripheral embolism or stent thrombosis) in patients on DAPT (aspirin +
clopidogrel), vs. TT (DAPT + oral anticoagulant).
Results: Baseline characteristics in the TT and DAPT groups were similar for age (72
 9 vs. 70  10 years; P¼0.25), gender (29 vs. 27% females, P¼0.73),
CHA2DS2VASc score >1 (91 vs. 86%, P¼0.25), and ejection fraction <30% (12 vs.
9%, P¼0.34). The TT group had shorter lesions and stents compared to those on
DAPT (25  19 vs. 30  19 mm, P¼0.02). Mean duration of clopidogrel therapy was
similar, as was the use of bare-metal stents. At 1-year, rates of MACCE (22 vs. 20%;
P¼0.71, Figure 1.), stroke (1.2 vs. 0.6%, P¼0.13); major bleeding (3 vs. 1%, P¼0.37)ber 1, 2013 j TCT Abstracts/POSTER/Antiplatelets and Antithrombins
